Stimulation of insulin-like growth factor (IGF)-1 receptor by IGF-1 and insulin strongly induces cardiomyocyte hypertrophy. In this study, we assessed the hypothesis that genetic variations of the IGF-1 receptor may be linked to the diversity of left ventricular (LV) structure in hypertensive patients. Genotypes in 12 single nucleotide polymorphisms (SNPs) of the IGF-1 receptor gene identified by direct sequencing were determined in 795 Japanese patients with essential hypertension. In echocardiographic examinations, LV mass index (LVMI) and relative wall thickness (RWT) were measured. Among 12 SNPs, promoter À328C4T and intron-13 275124A4C polymorphisms were significantly associated with LV hypertrophy (LVMIX125 g m -2 ) and concentric change (RWTX0.44), respectively. In allele frequencies, the C allele of À328C4T was related to LV hypertrophy, and the A allele of 275124A4C was related to LV concentric change. In fact, LVMI and prevalence of LV hypertrophy increased in CC genotype of -328C4T. RWT and prevalence of LV concentric change increased in AA genotype of 275124A4C. A multiple logistic regression analysis revealed that the presence of CC genotype of -328C4T or AA genotype of 275124A4C was an independent determinant for LV hypertrophy or concentric change, respectively. Furthermore, the combination of CC of À328C4T and AA of 275124A4C genotypes was significantly associated with abnormal LV geometry, especially concentric hypertrophy. Our findings show that two SNPs of the IGF-1 receptor gene are related to LV hypertrophy in patients with essential hypertension, suggesting that the genetic variation of the IGF-1 receptor may be involved in the diversity of LV structure in hypertensives.
Introduction
Left ventricular (LV) hypertrophy, the most common cardiac consequence of hypertension, is considered as a maladaptation to the increased afterload, because it is one of the independent risk factors for cardiovascular morbidity and mortality. 1 However, the haemodynamic load is not the only determinant of LV hypertrophy, because for similar elevations of blood pressure, a wide range of severities and types of LV hypertrophy have been observed. 2, 3 Many studies have shown that blood pressure explains only 10 to 25% of the variation in LV mass, supporting the hypothesis that several non-haemodynamic factors, such as genetic and metabolic factors, are involved in the cardiac growth in human hypertension. [4] [5] [6] Hypertension is one of the components of the metabolic syndrome, which is characterized by insulin-resistance and hyperinsulinemia. An earlier study has shown that circulating levels of insulin and insulin-like growth factor (IGF)-1 are associated with LV hypertrophy and geometric change in hypertensive subjects. 7 IGF-1 is a well-known strong promoter of cardiomyocyte growth through its receptors abundantly expressed in myocardium. 8 Insulin may also stimulate cardiomyocyte hypertrophy by binding to the IGF-1 receptors because of the structural similarity between the two molecules. 9, 10 The above considerations prompted us to hypothesize that the genetic variation of the IGF-1 receptor may be linked to the diversity of LV structure in hypertensives. Thus, this study analysed the association of IGF-1 receptor gene polymorphisms with LV mass and geometry in patients with essential hypertension.
Materials and methods

Subjects
A total of 795 Japanese patients with essential hypertension (438 men and 357 women; mean age, 65 ± 11 years) were enroled in this study. Patients with secondary hypertension, myocardial infarction, valvular heart disease, congestive heart failure, atrial fibrillation, or unsatisfactory B-mode and Doppler echocardiograms were excluded from this study. Hypertension was defined as a systolic blood pressure of X140 mm Hg and/or a diastolic blood pressure of X90 mm Hg by repeated measurements or when medication was taken for treatment of hypertension. Diabetes mellitus was diagnosed according to the American Diabetes Association criteria, such as a fasting plasma glucose of X126 mg per 100 ml and/or a plasma glucose level at 2 h after a 75 g oral glucose load of X200 mg per 100 ml, or when medication was taken for treatment of hyperglycaemia.
Among the 795 patients, 726 (91%) were receiving antihypertensive drugs, including combination therapy in some cases. In total, 574 patients (72%) were treated with calcium channel blockers, 407 (51%) with renin angiotensin system inhibitors (that is, angiotensin II receptor blockers and angiotensin converting enzyme inhibitors), 285 (36%) with bblockers, 181 (23%) with diuretics and 113 (14%) with other classes of agents. In all, 69 patients (9%) were treated with diet and/or exercise therapy (without antihypertensive medication).
All subjects gave their informed consent to participate in this study. The study protocol was approved by the ethical review committee of the National Cardiovascular Center.
Clinical parameters
At the time of the physical examination, blood pressure, heart rate, body mass index and biochemical profiles were determined. Blood pressure and heart rate were measured in the subjects after at least 10 min of rest in a sitting position. Peripheral blood samples were obtained in the morning after an overnight fast. Total cholesterol, triglycerides, fasting plasma glucose, haemoglobin A1c and serum creatinine levels were determined by standard laboratory measurements.
Echocardiographic measurement
A comprehensive two-dimensional echocardiography was performed using a cardiac ultrasound unit (Sonos 5500; Philips Medical Systems, Andover, MA, USA) as described earlier. 11, 12 Echocardiographic parameters were measured by the consensus of two experienced investigators who were blinded to the clinical data of the subjects. Measurements, such as interventricular septal thickness (IVSTd), posterior wall thickness (PWTd), LV diameter at end-diastole (LVDd) and LV diameter at end-systole (LVDs). Fractional shortening was calculated as (LVDd-LVDs)/LVDd. Relative wall thickness (RWT) was calculated as (IVSTd þ PWTd)/LVDd. LV mass was estimated using the formula validated by Devereux and Reichek:
3 ÀLVDd 3 }À13.6. LV mass was normalized for body surface area and expressed as LV mass index (LVMI). LV hypertrophy and LV concentric change were defined as a LVMI of X125 g m -2 and a RWT of X0.44, respectively.
2,3
The geometry of LV was stratified into four different patterns according to the values of LVMI (o or X125 g m -2 ) and RWT (o or X0.44). Patients with increased LVMI and increased RWT were considered to have concentric hypertrophy, and those with increased LVMI and normal RWT were considered to have eccentric hypertrophy. Those with normal LVMI and increased or normal RWT were considered to have concentric remodelling or normal geometry, respectively.
To assess LV diastolic function, the diastolic filling of LV (LV inflow) was examined using Doppler echocardiography.
14 The peak velocity of early diastolic filling (E) and the peak velocity of atrial filling (A) were recorded and the E to A ratio (E/A) was calculated. The deceleration time was measured as the time between the top of the E wave and the point at which the descending part of the E wave or its asymptote crossed the zero line.
Detection and genotyping of single nucleotide polymorphisms (SNPs) First, peripheral blood samples were obtained from 96 patients with essential hypertension, and all exons, part of the intron segments, and the promoter regions of the IGF-1 receptor gene were sequenced for the detection of SNPs. The method of direct sequencing has been described earlier. 15, 16 The identified polymorphisms were numbered from the A of the initiator codon (ATG), according to the recommendations of the Nomenclature Working Group for human gene mutations. 17 Among all SNPs identified by sequencing, common SNPs with a minor allele frequency of 45% were chosen, and one SNP from several SNPs with tight linkage disequilibrium (r 2 X0.5) was selected for genotyping. As a result, 12 SNPs were genotyped using the TaqManpolymerase chain reaction system for all patients, as described earlier.
18,19
Statistical analysis
The values are expressed as mean ± s.d. To assess the association of IGF-1 receptor SNPs with LV structural change, differences in frequency among the groups were tested by w 2 analysis. An unpaired Student's t-test was used for comparison of clinical and echocardiographic parameters between the two groups with different SNP genotypes. A multiple IGF-1 receptor gene polymorphism and LVH T Horio et al logistic regression analysis was performed to identify the independent relation of some SNPs to LV hypertrophy and geometric change. HardyWeinberg equilibrium was calculated using a w 2 test. A value of Po0.05 was accepted as statistically significant. All analyses were performed using StatView Version 5 Software (Abacus Concepts Inc., Berkeley, CA, USA). Linkage disequilibrium was evaluated by obtaining an r 2 value between polymorphisms using the SNP Alyze ver. 2.0 software (DYNACOM Co, Ltd, Shigehara, Japan).
Results
Locations of identified and genotyped SNPs in the IGF-1 receptor gene were shown in Figure 1 . In total, 12 SNPs (three SNPs in promoter, one in exon and eight in intron regions) in the IGF-1 receptor gene were genotyped in the present study. In all, 11 of 12 SNPs had been recorded in public databases (dbSNPs, http://www.ncbi.nlm.nih.gov/SNP/), and the remaining one SNP (À1760C4G) was novel. The genotype distribution of all analysed SNPs did not significantly deviate from the Hardy-Weinberg expectation.
The association of SNP genotypes in the IGF-1 receptor gene with LV structural change was assessed by w 2 analysis (Table 1) . Among 12 SNPs, genotype frequencies of promoter À328C4T and intron-13 275124A4C polymorphisms were significantly associated with LV hypertrophy (w 2 ¼ 7.513 and P ¼ 0.023) and LV concentric change (w 2 ¼ 7.949 and P ¼ 0.019), respectively. Similarly, in allele frequencies, the C allele of À328C4T had a significant relation to LV hypertrophy (odds ratio 1.78, w 2 ¼ 6.828 and P ¼ 0.009), and the A allele of 275124A4C was related to LV concentric change (odds ratio 1.38, w 2 ¼ 7.259 and P ¼ 0.007). Next, we compared clinical characteristics and echocardiographic parameters between different genotype groups of IGF-1 receptor À328C4T and 275124A4C polymorphisms. There were no significant differences in clinical parameters, such as age, sex, body mass index, hypertension duration, blood pressure and the use of antihypertensive agents between the two subject groups with CC (n ¼ 702) and CT þ TT (n ¼ 92) of -328C4T (Table 2) . However, LV wall thickness, LVMI, and the prevalence of LV hypertrophy were significantly increased in the group with CC genotype. LV systolic and diastolic function (fractional shortening, E/A ratio and deceleration time) did not differ between the two groups. As for 275124A4C polymorphism, similarly, no significant differences were found in clinical characteristics between the two-genotype groups with AA (n ¼ 470) and AC þ CC (n ¼ 321) (Table 3) . 58546C>T  263443T>C  263743G>A  272663C>T  275124A>C  275133-275134delGT  279924T>C h  280796A>G  285415G>A h  285903T>C h  299235G>A  299251G>A i  307446G>A i   21  20  17  16  15  14  13  11  8 5) , and the underlined 12 SNPs were genotyped in this study. In all, 11 of 12 genotyped SNPs had been recorded in public databases (dbSNPs); that is, À2210G4A was identical to dbSNP ID rs8034564, À328C4T to rs13379905, 58546C4T to rs7174918, 263443T4C to rs2272037, 263743G4A to rs951715, 272663C4T to rs3743262, 275124A4C to rs1464430, 279924T4C to rs4486868, 280796A4G to rs2229765, 299235G4A to rs2684789 and 307446G4A to rs2593053. 
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Among echocardiographic parameters, interventricular septal thickness, RWT and the prevalence of LV concentric change were significantly increased in the group with AA genotype, although LV dimension, LVMI, and LV systolic and diastolic function did not differ between the two groups.
To confirm whether the influence of these specific SNP genotypes in the IGF-1 receptor gene on LV structural changes was independent of various clinical parameters, we analysed possible predictive factors using a multiple logistic regression analysis in all subjects. As shown in Table 4 , the presence of CC genotype of -328C4T was a significant predictor of LV hypertrophy, independent of age, sex, body mass index, hypertension duration, complication of diabetes mellitus, and systolic and diastolic blood pressure (odds ratio 1.67 vs CT þ TT and P ¼ 0.033). In addition, AA genotype of 275124A4C was found to be an independent determinant for LV concentric change (odds ratio 1.37 vs AC þ CC and P ¼ 0.039).
Finally, the combined effect of CC of À328C4T and AA of 275124A4C genotypes on LV geometric patterns was analysed. The patient group with both CC genotype of À328C4T and AA genotype of 275124A4C (group 2, n ¼ 424) had a significantly higher rate of LV concentric hypertrophy compared with the other subjects (group 1, n ¼ 366) (Figure 2 ). In contrast, the rate of patients with normal geometry was significantly lower in group 2 than in group 1. There were no differences in basal 
clinical characteristics and antihypertensive treatment between the two groups (data not shown).
Discussion
Earlier studies have revealed that a promoter polymorphism in the IGF-1 gene is related to several cardiovascular complications, such as myocardial infarction, heart failure and cardiac hypertrophy. [20] [21] [22] [23] On the other hand, the genetic variations in the IGF-1 receptor have been shown to be associated with non-cardiovascular human disorders, such as growth retardation, cancer, dementia and osteoporosis. [24] [25] [26] [27] However, because IGF-1 receptor expression is also observed in the cardiovascular system, especially abundantly in the heart, the possible association of IGF-1 receptor gene polymorphisms with cardiac structure and function should be elucidated. In this study, we showed that two SNPs of the IGF-1 receptor gene, promoter À328C4T and intron-13 275124A4C, were significantly associated with LV hypertrophy in hypertensive patients. Thus, this is the first study that reported the significant influence of the IGF-1 receptor gene variation on cardiac hypertrophic change in human hypertension.
This study also showed that the combination of IGF-1 receptor À328C4T and 275124A4C polymorphisms was related to specific patterns of LV geometry. The patients with both CC genotype of -328C4T and AA genotype of 275124A4C had a significantly higher rate of LV concentric hypertrophy compared with the other subjects. These findings suggest the possibility that blood pressure level-independent diversity of LV structure in hypertensives is partially attributable to the genetic variation of the IGF-1 receptor. In addition, as for the association between LV geometry and cardiovascular prognosis, hypertensive patients with concentric hypertrophy among four LV geometric patterns have the highest incidence of cardiovascular events and death. 2, 28 Therefore, having both CC genotype of À328C4T and AA genotype of 275124A4C may be a risk marker for poor cardiovascular prognosis in hypertensive subjects.
Our earlier in vitro study showed that IGF-1 promotes not only hypertrophy of cardiomyocytes but also collagen production by cardiac fibroblasts. 29 As cardiac fibrosis induces the deterioration of LV function, we examined whether À328C4T and 275124A4C polymorphisms were associated with LV systolic and diastolic dysfunction as well as LV hypertrophy. However, neither systolic function (fractional shortening) nor diastolic function (E/A ratio and deceleration time) had a significant association with these SNPs. Therefore, it is unlikely that LV function, apart from LV hypertrophy, may be influenced by IGF-receptor gene polymorphisms. Figure 2 The combined effect of CC of À328C4T and AA of 275124A4C genotypes in the insulin-like growth factor (IGF)-1 receptor gene on left ventricular (LV) geometric patterns. Group 2 indicates the subjects with both CC genotype of À328C4T and AA genotype of 275124A4C, and the other subjects (that is, with CT þ TT of -328C4T and/or AC þ CC of 275124A4C) belong to group 1. CR, concentric remodelling (normal LVMI and increased RWT); CH, concentric hypertrophy (increased LVMI and RWT); EH, eccentric hypertrophy (increased LVMI and normal RWT); NG, normal geometry (normal LVMI and RWT). *Po0.05 compared with group 1.
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This study has not provided specific information regarding the mechanism by which the observed SNPs of the IGF-1 receptor gene influence LV mass and geometry. That is, it remains unclear whether these SNPs are functional or just risk markers. As À328C4T polymorphism is present in the promoter region, this SNP may affect the expression level of the IGF-1 receptor gene. On the other hand, 275124A4C polymorphism in intron-13 does not functionally affect the expression of the IGF-1 receptor protein. Further studies will be necessary to clarify the function of these polymorphisms or to identify the causative polymorphisms that are in linkage disequilibrium with these polymorphisms.
In addition, it remains to be elucidated whether the significant association of IGF-1 receptor gene polymorphisms with LV hypertrophy observed in hypertensive patients is also seen in other cardiac diseases, such as hypertrophic cardiomyopathy, valvular heart disease and old myocardial infarction.
In conclusion, this study showed that two SNPs of the IGF-1 receptor gene, promoter À328C4T and intron-13 275124A4C, were significantly associated with LV hypertrophy, and that the combination of these two polymorphisms was related to specific patterns of LV geometry in patients with essential hypertension. Thus, the genetic variation of the IGF-1 receptor may be involved in the diversity of LV structure in hypertensives, particularly in the progression of LV concentric hypertrophy.
